These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 21518347)
1. Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder. Alloway TP Dev Med Child Neurol; 2011 Sep; 53(9):780. PubMed ID: 21518347 [No Abstract] [Full Text] [Related]
2. Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate. Slama H; Fery P; Verheulpen D; Vanzeveren N; Van Bogaert P J Child Neurol; 2015 Jul; 30(8):1000-9. PubMed ID: 25296928 [TBL] [Abstract][Full Text] [Related]
3. Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder. Blum NJ; Jawad AF; Clarke AT; Power TJ Dev Med Child Neurol; 2011 Sep; 53(9):843-849. PubMed ID: 21585365 [TBL] [Abstract][Full Text] [Related]
4. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate. Kim E; Cheon KA; Joung YS; Kim JY; Song DH Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917 [TBL] [Abstract][Full Text] [Related]
5. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067 [TBL] [Abstract][Full Text] [Related]
6. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials. Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428 [TBL] [Abstract][Full Text] [Related]
7. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder. Golubchik P; Kodesh A; Weizman A Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551 [TBL] [Abstract][Full Text] [Related]
8. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder. Ince Tasdelen B; Karakaya E; Oztop DB J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871 [TBL] [Abstract][Full Text] [Related]
9. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? Killeen MR J Child Fam Nurs; 2000; 3(1):46-8. PubMed ID: 11022478 [No Abstract] [Full Text] [Related]
11. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'. Olders H J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567 [No Abstract] [Full Text] [Related]
12. Resolution of methylphenidate osmotic release oral system-induced hair loss in two siblings after dose escalation. Ardic UA; Ercan ES Pediatr Int; 2017 Nov; 59(11):1217-1218. PubMed ID: 29359460 [TBL] [Abstract][Full Text] [Related]
13. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533 [TBL] [Abstract][Full Text] [Related]
14. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Gau SS; Shen HY; Soong WT; Gau CS J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569 [TBL] [Abstract][Full Text] [Related]
15. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689 [No Abstract] [Full Text] [Related]
16. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Marcus SC; Wan GJ; Kemner JE; Olfson M Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858 [TBL] [Abstract][Full Text] [Related]
17. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder. Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694 [TBL] [Abstract][Full Text] [Related]